Solventum earnings release, May 5, 2026
Solventum Reports First Quarter 2026 Financial Results
• R eported sales decreased (3.0)%; organic sales increased 2.1%
• Affirms full-year 2026 organic sales growth and free cash flow guidance; estimates adjusted EPS will be toward the high end of existing range
EAGAN, Minn., May 5, 2026 – Solventum (NYSE: SOLV) today reported financial results for the first quarter ended March 31, 2026.
First Quarter 2026 Highlights
• S ales of $2.0 billion decreased (3.0)% on a reported basis; an increase of 2.1% on an organic basis
• G
AAP diluted earnings per share of $0.07; adjusted diluted earnings per share of $1.48, a 10.6% increase
• Operating cash flow of $(189) million; free cash flow of $(273) million
“Solventum delivered first quarter results ahead of expectations, reflecting strong execution and underlying commercial momentum,” said Bryan Hanson, chief executive officer of Solventum. “The work we’re doing to transform the company is reinforcing our confidence in the full year and accelerating progress toward our long-range plan.”
First Quarter 2026 Financial Results¹
Represents non-GAAP financial measure; see the “Non-GAAP Financial Measures” section for applicable information.
Discussion of First Quarter Results
All comparisons are to the prior year period unless otherwise noted
• Organic sales growth of +
2.1% in the quarter reflects strong performance across all reportable segments, primarily driven by volume and product mix.
• GAAP and adjusted gross margin both increased by 80 bps due to programmatic savings, portfolio moves, sales leverage and mix, partially offset by tariffs and inflation headwinds.
• Selling, general and administrative expenses increased primarily due to higher costs associated with separation activities and Transform for the Future, partially offset by restructuring benefits.
• GAAP operating income margin decreased driven by separation and restructuring costs while adjusted operating income margin decreased primarily due to tariffs and inflation, partially offset by operational improvements.
• Operating cash flow for the quarter was
$(189) million and free cash flow was
$(273) million, driven by separation activities, transition agreement exit payments and normal seasonality.¹
Other Business and Operational Highlights
• Celebrated the grand opening of a new 250,000 square foot flagship R&D center of excellence in Eagan, Minnesota, featuring modern workspaces, a pilot factory and a dedicated quality lab to fuel a steady pipeline of healthcare innovation.
• Completed a manufacturing expansion in Brookings, South Dakota, adding 200,000 square feet, 16 shipping docks and an 8,000-pallet warehouse to strengthen production capacity and speed innovations from lab to clinicians.
*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum. “NM” reflects results considered not meaningful due to sale of the Purification and Filtration business in September 2025.²
Constant currency represents the change in net sales absent the impact on sales from foreign currency translation.³
Other represents sales impact from acquisitions and divestitures measured separately for the first 12 months post-transaction. Acquisitions include sales from the December 2025 acquisition of Acera. Divestitures primarily represents lost sales from the Company’s Purification and Filtration business that was sold in September 2025.⁴
All Other includes the drinking water business, which was previously reported within Purification and Filtration, and sales related to product supplied to 3M and other supply agreements related to legacy 3M business and assumed by the Company at Spin-Off.
Full-Year 2026 Guidance
Solventum is affirming its full year 2026 guidance:
• Organic sales growth of +2.0% to +3.0%; +3.0% to +4.0% excluding ~100 bps of SKU exit impact
• Adjusted EPS estimated to be toward the high end of existing $6.40 to $6.60 guidance range
• Free cash flow of ~$200M
Organic sales, adjusted diluted EPS and free cash flow amounts included in Solventum’s full-year guidance are non-GAAP financial measures. Solventum does not provide reconciliations of the forward-looking non-GAAP financial measures to the respective GAAP metrics as it is unable to predict with reasonable certainty and without unreasonable effort certain items, such as the impact of changes in currency exchange rates, impacts associated with business acquisitions or divestitures, and the timing and magnitude of restructuring activities, among other items.
See the “Non-GAAP Financial Measures” section for explanations of our non-GAAP financial measures.
Earnings Conference Call
Solventum will host a conference call today, May 5, at 4:30 p.m. Eastern Time to discuss its first quarter financial results and fiscal year 2026 outlook. The conference call can be accessed via audio webcast at investors.solventum.com or by dialing (800) 715-9871 within the U.S. or +1 (646) 307-1963 for international callers, using the conference ID 6342275.²
A replay of the webcast, along with the earnings press release, slides highlighting the results and supplemental financial disclosures, will also be available at the same link on the Investor Relations section of the Company’s website.
Financial statements
Income Statement
Three months ended March 31, — First Quarter 2026 Financial Results (Dollars in millions, except per share amounts)
| Three months ended March 31, – 2026 | Three months ended March 31, – 2025 | Three months ended March 31, – Year-over-year change | |
|---|---|---|---|
| Net sales | 2,007 | 2,070 | -3 |
| Selling, general and administrative expenses | 827 | 769 | 7.5 |
| Research and development expenses | 189 | 193 | -2.1 |
| Operating income margin | 4.0% | 7.3% | (330) bps |
| Adjusted operating income margin1 | 19.5% | 19.7% | (20) bps |
| Net income | 13 | 137 | -90.5 |
| Diluted earnings per share | 0.07 | 0.78 | -91 |
| Adjusted diluted earnings per share1 | 1.48 | 1.34 | 10.6 |
| Net cash provided by (used in) operating activities | -189 | 29 | -751.7 |
| Free cash flow1 | -273 | -80 | -241.3 |
Income Statement
Three months ended March 31, — (Unaudited)
| Three months ended March 31, – 2026 | Three months ended March 31, – 2025 | ||
|---|---|---|---|
| Net sales of product | 1,513 | 1,597 | |
| Net sales of software and rentals | 493 | 473 | |
| Total net sales | 2,007 | 2,070 | |
| Cost of product | 796 | 835 | |
| Cost of software and rentals | 115 | 121 | |
| Gross profit | 1,097 | 1,114 | |
| Selling, general and administrative expenses | 827 | 769 | |
| Research and development expenses | 189 | 193 | |
| Operating income | 81 | 152 | |
| Interest expense, net | 62 | 104 | |
| Other expense (income), net | 4 | 11 | |
| Income before income taxes | 16 | 38 | |
| Provision for (benefit from) income taxes | 3 | -99 | |
| Net income | 13 | 137 | |
| Earnings per share: | Basic earnings per share | 0.07 | 0.79 |
| Earnings per share: | Diluted earnings per share | 0.07 | 0.78 |
| Weighted-average number of shares outstanding: | Basic | 174.2 | 173.7 |
| Weighted-average number of shares outstanding: | Diluted | 175.5 | 174.8 |
Income Statement
| BUSINESS SEGMENT INFORMATION AND DISAGGREGATED NET SALES* – Three months ended March 31, 2026 – Net sales | BUSINESS SEGMENT INFORMATION AND DISAGGREGATED NET SALES* – Three months ended March 31, 2026 – Operating income | BUSINESS SEGMENT INFORMATION AND DISAGGREGATED NET SALES* – Three months ended March 31, 2026 – Operating margin % | Three months ended March 31, 2025 – Net sales | Three months ended March 31, 2025 – Operating income | Three months ended March 31, 2025 – Operating margin % | |
|---|---|---|---|---|---|---|
| Advanced Wound Care | 497 | 448 | ||||
| Infection Prevention and Surgical Solutions | 737 | 710 | ||||
| MedSurg | 1,234 | 161 | 13.1% | 1,157 | 206 | 17.8% |
| Dental Solutions | 354 | 87 | 24.5% | 328 | 78 | 23.9% |
| Health Information Systems | 342 | 130 | 38.1% | 329 | 109 | 33.1% |
| Total reportable segment net sales and operating income | 1,931 | 379 | 1,814 | 393 | ||
| Purification and Filtration | NM | 180 | 27 | 15.1% | ||
| All Other | 76 | 12 | 15.4% | 76 | 11 | 15.2% |
| Amortization expense | -90 | -81 | ||||
| Corporate and unallocated | -219 | -198 | ||||
| Total Company | 2,007 | 81 | 4.0% | 2,070 | 152 | 7.3% |
Balance Sheet
December 31, — (Unaudited)
| March 31, – 2026 | December 31, – 2025 | ||
|---|---|---|---|
| Current assets | Cash and cash equivalents | 561 | 878 |
| Current assets | Accounts receivable — net of allowances of $87 and $87 | 1,059 | 1,034 |
| Current assets | Due from related parties | 121 | 150 |
| Inventories | Finished goods | 643 | 636 |
| Inventories | Work in process | 222 | 201 |
| Inventories | Raw materials and supplies | 224 | 229 |
| Inventories | Total inventories | 1,089 | 1,066 |
| Inventories | Other current assets | 754 | 731 |
| Inventories | Total current assets | 3,583 | 3,859 |
| Inventories | Property, plant and equipment — net | 1,543 | 1,326 |
| Inventories | Goodwill | 5,626 | 5,704 |
| Inventories | Intangible assets — net | 2,497 | 2,592 |
| Inventories | Other assets | 848 | 814 |
| Inventories | Total assets | 14,097 | 14,294 |
| Current liabilities | Short-term borrowings and current portion of long-term debt | 505 | |
| Current liabilities | Accounts payable | 699 | 687 |
| Current liabilities | Due to related parties | 337 | 435 |
| Current liabilities | Unearned revenue | 613 | 621 |
| Current liabilities | Other current liabilities | 1,192 | 1,393 |
| Current liabilities | Total current liabilities | 3,346 | 3,136 |
| Current liabilities | Long-term debt | 4,575 | 5,035 |
| Current liabilities | Pension and postretirement benefits | 360 | 363 |
| Current liabilities | Deferred income taxes | 161 | 164 |
| Current liabilities | Finance leases | 207 | |
| Current liabilities | Other liabilities | 478 | 547 |
| Current liabilities | Total liabilities | 9,128 | 9,245 |
| Equity | Common stock, par value $0.01 per share, 750,000,000 shares authorized | 2 | 2 |
| Shares - December 31, 2025: issued and outstanding: 173,490,864 | Additional paid-in capital | 3,895 | 3,876 |
| Shares - December 31, 2025: issued and outstanding: 173,490,864 | Retained earnings | 1,810 | 1,797 |
| Shares - December 31, 2025: issued and outstanding: 173,490,864 | Treasury stock, at cost | -67 | |
| Shares - December 31, 2025: 0 | Accumulated other comprehensive income (loss) | -670 | -625 |
| Shares - December 31, 2025: 0 | Total equity | 4,969 | 5,049 |
| Shares - December 31, 2025: 0 | Total liabilities and equity | 14,097 | 14,294 |
Cash Flow
Three months ended March 31, — (Unaudited)
| Three months ended March 31, – 2026 | Three months ended March 31, – 2025 | ||
|---|---|---|---|
| Cash flows from operating activities | Net income | 13 | 137 |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities | Depreciation and amortization | 135 | 129 |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities | Pension and postretirement benefit expense | 14 | 15 |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities | Stock-based compensation expense | 51 | 49 |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities | Deferred income taxes | -41 | -144 |
| Changes in assets and liabilities | Accounts receivable | -34 | 6 |
| Changes in assets and liabilities | Due from related parties | 28 | 5 |
| Changes in assets and liabilities | Inventories | -32 | -32 |
Cash Flow
Three months ended March 31, (in millions)
| Three months ended March 31, – 2026 | Three months ended March 31, – 2025 | ||
|---|---|---|---|
| Net cash provided by (used in) operating activities | -189 | 29 | |
| Net cash used in investing activities | -77 | -114 | |
| Net cash used in financing activities | -50 | -139 | |
| Free cash flow (non-GAAP measure) | Net cash provided by (used in) operating activities | -189 | 29 |
| Free cash flow (non-GAAP measure) | Purchases of property, plant and equipment | -84 | -109 |
| Free cash flow (non-GAAP measure) | Free cash flow | -273 | -80 |
Full release
Forward-Looking Statements
This... (truncated)herently uncertain and outside of Solventum’s control. Forward-looking statements include those containing such words as “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “guidance,” “intends,” “may,” “outlook,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “sees,” “should,” “targets,” “will,” “would” or other words of similar meaning or by using future dates in connection with the discussion of, among other things, statements expressing general views about future operating or financial results, operating or financial performance, trends, events or developments that we expect or anticipate will occur in the future, anticipated cost savings, the launch and acceptance of new products and changes in the global economic environment. It is possible that Solventum’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, including from risks and uncertainties related to, among others: competition and disruption in the healthcare industry; global economic, political and geopolitical conditions; changes in trade and tariff policies; changes in legislation or practices related to reimbursement, regulatory requirements and approvals; the development, manufacturing, marketing and sale of healthcare products; supply chain and operational execution; acquisitions, divestitures and other strategic transactions; Solventum’s separation from 3M and performance as a standalone company, including the tax-free nature of the spin and its ability to execute on its short- and long-range plans and capital allocation strategies; artificial intelligence, information technology and cybersecurity risks; restructuring programs, and other risks and uncertainties described in Solventum’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10‑K and Quarterly Report on Form 10‑Q. Solventum’s management believes that these forward-looking statements are reasonable as of the time made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. Solventum undertakes no obligation to update any forward‑looking statements or other information in this press release as a result of new information, future events or otherwise, except as required by applicable law.
Non-GAAP Financial Measures
In addition to reporting financial results in accordance with U.S. GAAP, Solventum also provides non-GAAP measures that we use, and plan to continue using, when monitoring and evaluating operating performance and measuring cash available to invest in our business. The adjusted measures are not in accordance with, nor are they a substitute for, GAAP measures. These non-GAAP financial measures are supplemental measures of our performance and our liquidity that we believe help investors understand our underlying business performance and Solventum uses these measures as an indication of the strength of Solventum and its ability to generate cash.
Solventum calculates forward-looking non-GAAP financial measures, including organic sales growth, adjusted gross margin, adjusted operating income, adjusted operating income margin, adjusted effective tax rate, adjusted diluted earnings per share and free cash flow based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. Solventum does not provide reconciliations of these forward-looking non-GAAP financial measures to the most directly comparable GAAP measures as it is unable to predict with reasonable certainty and without unreasonable effort certain items such as the impact of changes in currency exchange rates, impacts associated with business acquisitions or divestitures, and the timing and magnitude of restructuring activities, among other items. The timing and amounts of these items are uncertain and could have a material impact on Solventum’s results in accordance with GAAP.
The Q1 2026 financial statements and financial information, including reconciliations of non-GAAP financial measures, are available on Solventum’s website: investors.solventum.com.
About Solventum
At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients’ lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com.³
Solventum Investor Contact: investors@solventum.com
Solventum Media Contact: news@solventum.com⁴